These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 24158175)

  • 21. Comparative Efficacy of Beta-Lactams and Macrolides in the Treatment of Pediatric Pneumonia: A Systematic Review.
    Al Saeedy D; Gillani SW; Al-Salloum J; Moosvi A; Eissa M; Gulam SM
    Curr Pediatr Rev; 2020; 16(4):307-313. PubMed ID: 32895041
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is β-Lactam Plus Macrolide More Effective than β-Lactam Plus Fluoroquinolone among Patients with Severe Community-Acquired Pneumonia?: a Systemic Review and Meta-Analysis.
    Lee JH; Kim HJ; Kim YH
    J Korean Med Sci; 2017 Jan; 32(1):77-84. PubMed ID: 27914135
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fluoroquinolones or macrolides in combination with β-lactams in adult patients hospitalized with community acquired pneumonia: a systematic review and meta-analysis.
    Vardakas KZ; Trigkidis KK; Falagas ME
    Clin Microbiol Infect; 2017 Apr; 23(4):234-241. PubMed ID: 27965070
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Guideline-concordant antibiotic use and survival among patients with community-acquired pneumonia admitted to the intensive care unit.
    Frei CR; Attridge RT; Mortensen EM; Restrepo MI; Yu Y; Oramasionwu CU; Ruiz JL; Burgess DS
    Clin Ther; 2010 Feb; 32(2):293-9. PubMed ID: 20206787
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Beta-lactam plus macrolides or beta-lactam alone for community-acquired pneumonia: A systematic review and meta-analysis.
    Horita N; Otsuka T; Haranaga S; Namkoong H; Miki M; Miyashita N; Higa F; Takahashi H; Yoshida M; Kohno S; Kaneko T
    Respirology; 2016 Oct; 21(7):1193-200. PubMed ID: 27338144
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ceftriaxone versus ceftriaxone plus a macrolide for community-acquired pneumonia in hospitalized patients with HIV/AIDS: a randomized controlled trial.
    Figueiredo-Mello C; Naucler P; Negra MD; Levin AS
    Clin Microbiol Infect; 2018 Feb; 24(2):146-151. PubMed ID: 28648859
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of two guideline-concordant antimicrobial combinations in elderly patients hospitalized with severe community-acquired pneumonia.
    Wilson BZ; Anzueto A; Restrepo MI; Pugh MJ; Mortensen EM
    Crit Care Med; 2012 Aug; 40(8):2310-4. PubMed ID: 22622401
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment with macrolides and glucocorticosteroids in severe community-acquired pneumonia: A post-hoc exploratory analysis of a randomized controlled trial.
    Ceccato A; Cilloniz C; Ranzani OT; Menendez R; Agusti C; Gabarrus A; Ferrer M; Sibila O; Niederman MS; Torres A
    PLoS One; 2017; 12(6):e0178022. PubMed ID: 28617807
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Initial use of one or two antibiotics for critically ill patients with community-acquired pneumonia: impact on survival and bacterial resistance.
    Adrie C; Schwebel C; Garrouste-Orgeas M; Vignoud L; Planquette B; Azoulay E; Kallel H; Darmon M; Souweine B; Dinh-Xuan AT; Jamali S; Zahar JR; Timsit JF;
    Crit Care; 2013 Nov; 17(6):R265. PubMed ID: 24200097
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative effectiveness of empiric β-lactam monotherapy and β-lactam-macrolide combination therapy in children hospitalized with community-acquired pneumonia.
    Ambroggio L; Taylor JA; Tabb LP; Newschaffer CJ; Evans AA; Shah SS
    J Pediatr; 2012 Dec; 161(6):1097-103. PubMed ID: 22901738
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Initial antibiotic selection and patient outcomes: observations from the National Pneumonia Project.
    Bratzler DW; Ma A; Nsa W
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S193-201. PubMed ID: 18986289
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
    Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
    Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The need for macrolides in hospitalised community-acquired pneumonia: propensity analysis.
    Paul M; Nielsen AD; Gafter-Gvili A; Tacconelli E; Andreassen S; Almanasreh N; Goldberg E; Cauda R; Frank U; Leibovici L
    Eur Respir J; 2007 Sep; 30(3):525-31. PubMed ID: 17537772
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of Empiric Antibiotic Treatment Regimens for Hospitalized, Non-severe Community-acquired Pneumonia: A Retrospective, Multicenter Cohort Study.
    Reeves SD; Hartmann AP; Tedder AC; Juang PA; Hofer M; Kollef MH; Micek ST; Betthauser KD
    Clin Ther; 2024 Apr; 46(4):338-344. PubMed ID: 38403509
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The controversy of combination vs monotherapy in the treatment of hospitalized community-acquired pneumonia.
    Weiss K; Tillotson GS
    Chest; 2005 Aug; 128(2):940-6. PubMed ID: 16100190
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of antibiotic treatment strategies for community-acquired pneumonia: results from a cluster randomized cross-over trial.
    van Werkhoven CH; Postma DF; Mangen MJ; Oosterheert JJ; Bonten MJ;
    BMC Infect Dis; 2017 Jan; 17(1):52. PubMed ID: 28068956
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Hypothesis-Generating Study of the Combination of Aspirin plus Macrolides in Patients with Severe Community-Acquired Pneumonia.
    Falcone M; Russo A; Shindo Y; Farcomeni A; Pieralli F; Cangemi R; Liu J; Xia J; Okumura J; Sano M; Jones C; Vannucchi V; Mancone M; Micek S; Xu F; Violi F; Kollef M
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30509940
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Comparison of the combination and quinolone therapy in community acquired pneumonia].
    Kılıç Soylar Ö; Kılınç O; Ellidokuz H
    Tuberk Toraks; 2015 Sep; 63(3):165-9. PubMed ID: 26523897
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of empiric antimicrobial therapy with a β-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia.
    Mortensen EM; Restrepo MI; Anzueto A; Pugh J
    Crit Care; 2005 Dec; 10(1):R8. PubMed ID: 16420641
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Update on the combination effect of macrolide antibiotics in community-acquired pneumonia.
    Emmet O'Brien M; Restrepo MI; Martin-Loeches I
    Respir Investig; 2015 Sep; 53(5):201-9. PubMed ID: 26344609
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.